Collegium Pharmaceutical, Inc. · NASDAQ:COLL

Collegium Pharmaceutical — Q2 2022 Earnings Presentation

19 slides from Collegium Pharmaceutical's earnings presentation, Aug 4, 2022

1. Slide 1: Q2FY22 Earnings Report

   August 4, 2022 | Nasdaq: COLL Q2FY22 Earnings Report

2. Slide 2: Forward-Looking Statements

   Forward - Looking Statements This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "forecasts," "believes," "potential," "proposed," "continue," "estimates," "anticipates

3. Slide 3: Building a leading, diversified specialty pharmaceutical company

   Buildinga leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions I D E AUpholdI ntegrityEmbrace D ifferencesEncourage E xpressionBe A ccountableGUIDED BY OUR CORE VALUES Mission DrivenInvestor Presentation3

4. Slide 4: H1 2022 Key Business Highlights

   H1 2022 Key Business HighlightsInvestor Presentation G ROW T OP AND B OTTOM L INES Grew Belbuca®and Xtampza®ER prescriptions vs. H1 2021 Completed BDSI acquisition; On track to exceed run rate synergy target Delivered record net revenue $Renegotiated Xtampza ER contracts Resolved all 27 pending opio

5. Slide 5: Collegium 3-Phase Action Agenda

   Collegium 3-Phase Action Agenda PHASE1SEAMLESSINTEGRATION PHASE2GENERATEMOMENTUM PHASE3ACCELERATE1.Executed with no disruptions to core operations2.Achieved day one field force readiness3.Realized majority of targeted run rate synergies1.Grow Belbuca and Xtampza ER 2.Complete Xtampza ER contract ren

6. Slide 6: Top Capital Allocation Priority: Business Development

   BUSINESSDEVELOPMENTFOCUS•Differentiated commercial-stage assets•Peak sales potential >$150M•Exclusivity into 2030s Top Capital Allocation Priority: Business Development STRONGTRACKRECORDNucynta Franchise (February 2020)BDSI (March 2022) Investor Presentation6

7. Slide 7: Financial Highlights

   Financial HighlightsColleen Tupper, Executive Vice President & Chief Financial Officer

8. Slide 8: Q2FY22 Financial Highlights

   ESTIMATEDDEBT/EBITDA RATIO<3.0XBY2022 YEAR-END8Q2FY22 Financial Highlights11.This financial data was provided by Collegium Pharmaceutical, Inc. in its Quarterly Report on Form 10-Q filed with the SEC on August 4, 2022.2.Adjusted operating expenses is a non-GAAP financial measure. See Non-GAAP Financ

9. Slide 9: Updated 2022 Financial Guidance

   Updated 2022 Financial Guidance1$133M1.This financial data was provided by Collegium in its press release filed with the SEC on August 4, 2022.2.Adjusted operating expenses is a non-GAAP financial measure. See Non-GAAP Financial Measures on Slide 2. 3.Adjusted EBITDA is a non-GAAP financial measure.

10. Slide 10: Capital Allocation Priorities

    OPPORTUNISTICALLYRETURNCAPITALTOSHAREHOLDERS RAPIDLYPAYDOWNDEBT FOCUSEDBUSINESSDEVELOPMENTCapital Allocation Priorities•Commercial-stage assets:•With $150 million peak sales potential•Differentiated and durable with exclusivity into 2030s•>$50M remaining on $100M share repurchase program2•$650M Phar

11. Slide 11: Commercial Update

    Commercial UpdateScott Dreyer, Executive Vice President & Chief Commercial Officer

12. Slide 12: 2022 Commercial Priorities

    122022 Commercial Priorities Maximize Nucynta Franchise and Symproic Launch Elyxyb Achieve gross-to-net of <65% for Xtampza ER beginning in January 2023 Grow Belbuca and Xtampza ER

13. Slide 13: Strong and Growing Market Position

    ~19,200 unique prescribers in Q2FY22, up 1% vs. Q2FY21313The Leader in Responsible Pain ManagementInvestor Presentation 49.0%Branded ERMarket Share1,2+3.6% Over Q2FY21 Strong and Growing Market Position ~13,300 unique prescribers in Q2FY22, relatively stable vs. Q2FY213Sources:1.IQVIA NPA through Ju

14. Slide 14: H1 2022 Commercial Accomplishments and H2 2022 Priorities

    Collegium 3-Phase Action Agenda:H1 2022 Commercial Accomplishments and H2 2022 Priorities PHASE1SEAMLESSINTEGRATIONCompleted Investor Presentation141.Executed with no disruptions to core operations2.Achieved day one field force readinessHosted national sales meetingLaunched new Belbuca and Xtampza

15. Slide 15: Q&A

    Q&A

16. Slide 16: Building a Leading, Diversified Specialty Pharmaceutical Company

    DIVERSEANDDURABLEPORTFOLIO STRONGFINANCIALPOSITION LONG-TERMVALUECREATION 16Building a Leading, Diversified Specialty Pharmaceutical Company→Durable growth drivers→Leader in responsible pain market→Strategic foothold in neurology→Revenue expected to grow ~65% Y/Y1→Significant cost leverage: revenue

17. Slide 17: Non-GAAP Reconciliations

    Non-GAAP Reconciliations N

18. Slide 18: Reconciliation of GAAP Net Income to Adjusted EBITDA

    18Collegium Pharmaceutical, Inc.Reconciliation of GAAP Net Income to Adjusted EBITDA(in thousands)(unaudited) Three Months Ended June 30,20222021 GAAP Net (loss) income $ (5,191) $ 72,843 Adjustments: Interest expense17,7615,421Interest income (5) (3) Benefit from income taxes (1,455) (61,852) Depre

19. Slide 19: Reconciliation of GAAP Operating Expenses to Adjusted Operating Expenses

    19Collegium Pharmaceutical, Inc.Reconciliation of GAAP Operating Expenses to Adjusted Operating Expenses(in thousands)(unaudited) Three Months Ended June 30,20222021 GAAP Operating expenses $ 41,254 $ 33,830 Adjustments: Stock-based compensation5,6926,516Acquisition related expense3,579—Total adjust

Collegium Pharmaceutical — Q2 2022 Earnings Presentation on 6ix